Sandoz Group AG (SDZNY)
| Market Cap | 31.69B |
| Revenue (ttm) | 10.59B |
| Net Income (ttm) | 227.00M |
| Shares Out | n/a |
| EPS (ttm) | 0.52 |
| PE Ratio | 139.62 |
| Forward PE | 20.15 |
| Dividend | 0.57 (0.78%) |
| Ex-Dividend Date | Apr 22, 2025 |
| Volume | 3,178 |
| Average Volume | 24,119 |
| Open | 73.88 |
| Previous Close | 73.77 |
| Day's Range | 73.88 - 74.41 |
| 52-Week Range | 35.61 - 74.87 |
| Beta | 0.26 |
| RSI | 65.46 |
| Earnings Date | Feb 25, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
SDZNY vs. STVN: Which Stock Is the Better Value Option?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
Sandoz Completes Acquisition Of Just-Evotec Biologics
(RTTNews) - Sandoz (SDZ.SW) announced the completion of the acquisition of Just-Evotec Biologics EU SAS from Evotec SE. The deal includes the Toulouse development and manufacturing site and an indefin...
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's Why
Sandoz Group AG Sponsored ADR (SDZNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term...
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Sandoz Launches Wyost And Jubbonti In Europe
(RTTNews) - Sandoz (SDZ.SW) announced the European launch of Wyost and Jubbonti. The medicines are among the first denosumab biosimilars to launch in Europe and are approved to treat all indications o...
Sandoz Announces Launch Of TYRUKO In The US
(RTTNews) - Sandoz announced that TYRUKO or natalizumab-sztn is available to patients in the US. Developed by Polpharma Biologics, TYRUKO is the only FDA approved natalizumab biosimilar for the treatm...
James M. O'Brien Appointed Chief Financial Officer at Mesoblast
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection wi...
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wed...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
Sandoz To Acquire Just-Evotec Biologics EU SAS In Strategic Biosimilars Expansion Deal
(RTTNews) - Sandoz (SDZNY) announced a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS), including its Toulouse-based...
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec signs deal with Sandoz for Just - Evotec Biologics site
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Drugmakers must face skincare drug price-fixing lawsuit, US judge rules
A federal judge on Friday said 36 drugmakers and executives must face nearly all claims in an antitrust lawsuit brought by most U.S. states, accusing them of conspiring to fix prices of 80 generic dru...
SDZNY vs. STVN: Which Stock Is the Better Value Option?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Sandoz Group AG (SDZNY) Q3 2025 Sales Call Transcript
Sandoz Group AG (OTCQX:SDZNY) Q3 2025 Sales Call October 30, 2025 4:00 AM EDT Company Participants Craig Marks - Head of Investor Relations Richard Saynor - Chief Executive Officer Remco Steenbergen -...
Sandoz Group AG (SDZNY) Q3 2025 Sales/ Trading Statement Call - Slideshow
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
Sandoz granted tentative approval for generic of Pfizer's Inlyta
Sandoz gets FDA tentative approval for a generic of Pfizer’s kidney cancer drug Inlyta, but launch is delayed by patent litigation. Read more here.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
PRINCETON, N.J.--(BUSINESS WIRE)--Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent appro...
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar